Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain

Summary

The purpose of this study are to determine the effect FF-3 in comparison to placebo in subjects who are experimentally inoculated with a live, challenge strain of influenza A virus.

Timeline

Start

2015-09

Primary completion

2016-06

Completion

2016-06

Outcome

Missed primary endpoint

registry analysis (superiority test); FF-3 Dry Powder vs Placebo; p = 0.1436; Risk Ratio (RR) 1.14 (90% CI 0.98 to 1.31); Chi-squared NCT02423577 ↗

Drugs

Indications